Clinical trial • Phase III • Oncology
Clinical trial in Unresectable or metastatic solid tumours
Phase III trial for Unresectable or metastatic solid tumours. 24 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Unresectable or metastatic solid tumours
- Trial Stage
- Phase III
- Drug Modality
- Monoclonal antibody|Other
Key dates
- Initial CTIS Submission Date
- 10-11-2023
- First CTIS Authorization Date
- 29-02-2024
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 24
Recruitment
- Planned Sample Size
- 24
- Recruitment Window Months
- 36
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 24
Netherlands
- Earliest CTIS Part Ii Submission Date
- 01-02-2024
- Latest Decision Or Authorization Date
- 08-07-2024
- Processing Time Days
- 158
- Number Of Sites
- 1
- Number Of Participants
- 24
Sites
- Site Name
- Universitair Medisch Centrum Utrecht
- Department Name
- Medical oncology
- Contact Person Name
- Karijn Suijkerbuijk
- Contact Person Email
- k.suijkerbuijk@umcutrecht.nl
Sponsor
Primary sponsor
- Full Name
- Universitair Medisch Centrum Utrecht
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)